You are here

FDA Considers Labeling Update for Schizophrenia Drug Brexpiprazole (Rexulta)

Application seeks approval for maintenance treatment of adults with schizophrenia

The FDA has accepted for review a supplemental new drug application (sNDA) for a proposed labeling update of brexpiprazole (Rexulta, Otsuka/Lundbeck) for the maintenance treatment of adults with schizophrenia. The Prescription Drug User Fee Act (PDUFA) date is September 23, 2016.

The sNDA was supported by results from a 52-week randomized withdrawal trial in adults (18 to 65 years of age) with schizophrenia. Patients were stabilized on brexpiprazole and were then randomly assigned to continue therapy with brexpiprazole (n = 96) or placebo (n = 104). The study’s primary endpoint was the time from randomization to relapse. In a prespecified interim analysis, the study demonstrated a significantly longer time to relapse in the brexpiprazole group (1 to 4 mg/day) compared with the placebo group. The trial was terminated early because maintenance of efficacy had been demonstrated (P < 0.0001, final analysis).

The mechanism of action of brexpiprazole in the adjunctive treatment of major depressive disorder or schizophrenia is not known. However, the drug’s efficacy may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. Brexpiprazole exhibits high affinity (subnanomolar) for these receptors as well as for noradrenaline alpha1B/2C receptors. The drug was approved in the U.S. on July 10, 2015, as an adjunctive therapy to antidepressants in adults with major depressive disorder and as a treatment in adults with schizophrenia.

Source: Lundbeck; February 8, 2016.

More Headlines

Liver Fluke Infestation Affects Almost 2.5 Million People Globally
Policy Could Be Life-Changing for People With Spinal Cord Injury
Test Determines Severity of Pain, Helps Physicians Select Best Options
Intratumoral Injection Stimulates Immune Activation
Diabetes and Cancer Patients Could Soon Avoid Injections
Early Cancer Development May Begin in Just 30 Minutes
In Most Cases, Plaque/Tangle Dissolution Occurred Almost Instantly